Open access
Oct 2026
Anti-TNFR2 antibody BI-1808 induces tumor regression and antitumor T cell immunity through T reg and myeloid cell modulation in patients with solid tumors.
PURPOSE To clinically evaluate the safety, pharmacodynamic biomarkers, and efficacy of BI-1808, a first-in-class ligand-blocking, Fcγ receptor-engaging anti-TNFR2 antibody, as a novel immunotherapy approach to enhance antitumor immunity in solid cancer patients. EXPERIMENTAL DESIGN Preclinical modeling in syngeneic t...
I. Teige, K. Rohrberg, A. Carneiro et al.
· Clinical Cancer Research · 0 citations